WorldCat Identities

Tubiana, Roland

Overview
Works: 15 works in 16 publications in 2 languages and 31 library holdings
Roles: Contributor, Thesis advisor, Author, Opponent
Publication Timeline
.
Most widely held works by Roland Tubiana
VIH et sida : prise en charge et suivi du patient by Christine Katlama( )

2 editions published in 2011 in French and English and held by 8 WorldCat member libraries worldwide

Ces dix dernières années, l'utilisation des trithérapies antirétrovirales a permis une réduction spectaculaire de la mortalité et de la morbidité de l'infection à VIH. Le patient séropositif peut vivre de longues années avec la maladie en suivant un traitement au long cours mais nécessite toutefois une attention particulière de la part de son médecin. Afin d'aider le médecin traitant à mieux suivre son patient et soigner ses pathologies courantes, cet ouvrage, véritable guide pratique, s'applique à : spécifier l'importance du dépistage, ses modalités et les stratégies de préventio
Perinatal acquisition of drug-resistant HIV-1 infection: mechanisms and long-term outcome by ANRS French Perinatal Cohort( )

1 edition published in 2009 in English and held by 2 WorldCat member libraries worldwide

Is access to care different for women from sub-Saharan Africa than for French women according to prevention of mother-to-child HIV transmission in France? by ANRS French Perinatal Cohort EPF( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Is marital status and information of the father associated with access to prevention of mother-to-child HIV transmission? by Carine Jasseron( )

1 edition published in 2009 in English and held by 2 WorldCat member libraries worldwide

High prevalence of cytomegalovirus (CMV) infection in infants born to HIV infected mothers-ANRS French Perinatal Cohort (EPF) by ANRS French Perinatal Cohort (EPF)( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Pharmacocinétique de population des antirétroviraux chez la femme enceinte by Nedjma Sihem Benaboud( )

1 edition published in 2012 in French and held by 2 WorldCat member libraries worldwide

Important physiological changes occur during pregnancy. These changes may affect the pharmacokinetics and/or pharmacodynamics of the administered medication. In HIV infected women, antiretroviral treatment adequacy and effectiveness is essential for the health of the mother and for the prevention of HIV transmission to the newborn. For optimal treatment interms of efficacy and tolerance, the effect of pregnancy on antiretroviral concentrations in themother and their transplacental passage have to be assessed.In this work we used the appropriate methodology in this population: non linear mixed effects modeling. Data from therapeutic drug monitoring, as well as data from a multicenter clinical trial (TEmAA) were analyzed using: NONMEM or Monolix. In the first study presented, we investigated the pharmacokinetics of tenofovir in pregnant women. We observed a relatively large effect of pregnancy, a 39% increase of the apparent clearance in pregnant and parturient woman. A dose increase should be therefore investigated in these women. In the second study, we demonstrated a slight increase in lamivudine exposure during pregnancy. This increase does not require dose adjustment. In the third study, the concentration of nevirapinein the mother and her newborn were analyzed and the administration scheme was evaluated.In the last study, based on concentrations of tenofovir and emtricitabine in breast milk that arereported here for the first time in humans, we simulated the concentration profiles obtained ininfants
SPORT ET OBESITE DE L'ADOLESCENT : UN PROGRAMME D'ACTION PHYSIQUE POUR DE JEUNES OBESES SOUS REGIME TRES HYPOCALORIQUE by ROLAND TUBIANA( Book )

1 edition published in 1985 in French and held by 2 WorldCat member libraries worldwide

Mother-to-child transmission of HIV-1 drug resistance in a French cohort by Frédéric Benizri( )

1 edition published in 2008 in English and held by 2 WorldCat member libraries worldwide

Risk of cancer in children exposed to didanosine in utero( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Abstract : Background: Evaluation of long-term tolerance to antiretroviral exposure during pregnancy is required. An increased risk of cancer has been suggested in children exposed in utero to didanosine. Methods: Updated evaluation of cancer incidence in uninfected children exposed to nucleos(t)ide reverse transcriptase inhibitors (NRTIs) in the French perinatal study of children born to HIV+ mothers, by cross-checking with the National Cancer Registry. Associations between cancer risk and exposure to NRTIs were evaluated by univariate survival analysis and Cox proportional hazard models. Standardized incidence ratios (SIR) were used for comparison with the general population. Results: A total of 21 cancers were identified in 15 163 children (median age: 9.9 years [interquartile range (IQR): 5.8-14.2]) exposed to at least one NRTI in utero, between 1990 and 2014. Five children were exposed to zidovudine monotherapy, and 16 to various combinations, seven including didanosine. Didanosine accounted for only 10% of prescriptions but was associated with one-third of cancers. In a multivariate analysis, didanosine exposure was significantly associated with higher risk [hazard ratio = 3.0 (0.9-9.8)]. The risk was specifically linked with first-trimester exposure [hazard ratio = 5.5 (2.1-14.4)]. Overall, the total number of cases was not significantly different from that expected for the general population [SIR = 0.8 (0.47-1.24)], but was twice that expected after didanosine exposure [SIR = 2.5 (1.01-5.19)]. Conclusion: There are strong arguments to suggest that didanosine displays transplacental oncogenicity. Although not extrapolable to other NRTIs, they stress the need for comprehensive evaluation of the transplacental genotoxicity of this antiretroviral class. Abstract : Supplemental Digital Content is available in the text
Minority resistant variants are also present in HIV-2-infected antiretroviral-naive patients( )

1 edition published in 2018 in English and held by 1 WorldCat member library worldwide

Abstract Objectives To assess the prevalence of minority resistant variants (MRV) and X4-tropic minority variants in ART-naive HIV-2-infected patients. Patients and methods ART-naive HIV-2-infected patients with detectable plasma viral load (>100 copies/mL) included in the ANRS HIV-2 CO5 Cohort were assessed. We performed ultra-deep sequencing (UDS) of protease, RT, integrase and gp105 regions. Only mutations in the HIV-2 ANRS list>1% were considered. HIV-2 tropism was assessed by V3 loop region UDS, and each read was interpreted with determinants of CXCR4-coreceptor use. Results Among the 47 patients assessed, three displayed plasma viruses with a resistance-associated mutation (RAM) above the 20% detection threshold, all in RT, resulting in a prevalence of transmitted drug resistance for NRTI of 7.9% (95% CI 0.0%-16.5%). No RAM above the 20% detection threshold was found in protease or integrase. At the 1% detection threshold the transmitted drug resistance prevalence was 9.8% (95% CI 0.6%-19.0%), 13.2% (95% CI 3.5%-22.9%) and 4.5% (95% CI 0%-17.5%) for PI, NRTI and integrase inhibitors. The most prevalent MRV was the PI RAM I50V detected in three samples. Tropism analysis showed that 21% of patients (4 of 19) exhibited X4-tropic viruses: two in majority proportion and two in minority proportions (1.5% and 1.9%). Conclusions In this first study assessing the prevalence of MRV in HIV-2 infection among ART-naive patients, we observed a 2-3-fold higher prevalence of RAM when a 1% detection threshold of mutations was used compared with a 20% threshold. Similarly, the proportion of patients with X4-tropic viruses was twice as high when UDS was used
Treatment interruption in chronically HIV-infected patients with an ultralow HIV reservoir( )

1 edition published in 2016 in English and held by 1 WorldCat member library worldwide

Silent Cerebral Small-Vessel Disease Is Twice as Prevalent in Middle-Aged Individuals With Well-Controlled, Combination Antiretroviral Therapy-Treated Human Immunodeficiency Virus (HIV) Than in HIV-Uninfected Individuals( )

1 edition published in 2017 in English and held by 1 WorldCat member library worldwide

Abstract Background Silent cerebral small-vessel disease (CSVD) is defined as white matter hyperintensities, silent brain infarction, or microbleeds. CSVD is responsible for future vascular events, cognitive impairment, frailty, and shorter survival. CSVD prevalence among middle-aged people living with well-controlled human immunodeficiency virus (HIV) infection (PLHIV) is unknown. Methods The French National Agency for Research on AIDS and Viral Hepatitis (ANRS) EP51 Microvascular Brain Retina and Kidney Study (MicroBREAK; NCT02082574) is a cross-sectional study with prospective enrollment of treated PLHIV, e"0 years old with viral load controlled for e"2 months, and frequency age- and sex-matched HIV-uninfected controls (HUCs). It was designed to estimate CSVD prevalence on 3T magnetic resonance imaging (3D fluid-attenuated inversion recovery, transversal T2-weighted gradient-echo imaging and diffusion-weighted imaging), as diagnosed by 2 blinded neuroradiologists. A logistic regression model was used to assess the impact of HIV on CSVD after adjustment for traditional risk factors. Results Between June 2013 and May 2016, 456 PLHIV and 154 HUCs were recruited. Median age was 56 and 58 years, respectively (P = .001), among whom 84.9% and 77.3%, respectively (P = .030), were men. CSVD was detected in 51.5% of PLHIV and 36.4% of HUCs with an adjusted odds ratio (aOR) of 2.3. The HIV impact differed according to age, with aOR values of 5.3, 3.7, and 1.0 for age groups <54, 54-60, and>60 years, respectively (P = .022). Older age, hypertension, and lower CD4 cell count nadir were independently associated with a higher risk of CSVD among PLHIV. Conclusions HIV is an independent risk factor for CSVD. Despite sustained immunovirological control, the CSVD prevalence was twice as high among middle-aged PLHIV than HUCs. Clinical Trials Registration NCT02082574
 
moreShow More Titles
fewerShow Fewer Titles
Audience Level
0
Audience Level
1
  Kids General Special  
Audience level: 0.90 (from 0.76 for SPORT ET O ... to 0.97 for Is access ...)

Languages
English (11)

French (5)